Background: Coronavirus disease 2019 (COVID-19)–related critical illness and acute illness
are associated with a risk of venous thromboembolism (VTE). Objective: These evidence …

This article describes the pharmacology of approved parenteral anticoagulants. These
include the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight …

This article discusses the prevention of venous thromboembolism (VTE) and is part of the
Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence …

Abstract Background: COVID-19–related critical illness is associated with an increased risk
of venous thromboembolism (VTE). Objective: These evidence-based guidelines of the …

Objective To develop practical recommendations for the use of low-molecular-weight
heparins (LMWHs) as prophylaxis and treatment of venous thromboembolism and acute …

Anticoagulants remain the primary strategy for the prevention and treatment of thrombosis.
Unfractionated heparin, low molecular weight heparin, fondaparinux, and warfarin have …

For more than 60 years, heparin and coumarin have been mainstays of anticoagulation
therapy. They are widely available, inexpensive, effective, and have specific antidotes but …

This article discusses the prevention of venous thromboembolism (VTE) and is part of the
Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence …

Malignant conditions are frequently associated with a hypercoaguable state, with recurrent
thrombosis due to the impact of cancer cells and chemotherapy or radiotherapy on the …

With the rising prevalence of kidney disease, clinicians are increasingly faced with concerns
about potential thrombotic and bleeding complications. Thrombotic risk, both arterial and …